Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease muscular atrophy
Comorbidity C0018801|heart failure
Sentences 15
PubMedID- 24858848 These findings define novel roles for hdac6 in striated muscle and suggest potential for hdac6-selective inhibitors for the treatment of cardiac dysfunction and muscle wasting in patients with heart failure.
PubMedID- 21403882 Moreover, ghrelin administration increases exercise capacity and improves left ventricular function and muscle wasting in patients with chronic heart failure [94–96].
PubMedID- 26449626 Detection of muscle wasting in patients with chronic heart failure using c-terminal agrin fragment: results from the studies investigating co-morbidities aggravating heart failure (sica-hf).
PubMedID- 23656525 Other studies discussed here embraced the course of body wasting, particularly cachexia, and muscle wasting in patients with heart failure and the influence of eating behavior.
PubMedID- 21421824 Recently, myostatin, a cytokine from the transforming growth factor-beta (tgf-beta) family and a known strong inhibitor of skeletal muscle growth, has been identified as a direct mediator of skeletal muscle atrophy in mice with heart failure.
PubMedID- 25625009 Background: circulating angiotensin ii (angii) is elevated in congestive heart failure (chf), and leads to skeletal muscle wasting, which is strongly associated with poor patient outcomes.
PubMedID- 21235761 Skeletal muscle wasting associated with congestive heart failure is part of a general wasting syndrome associated with chf known as cardiac cachexia [34].
PubMedID- 20798901 These results suggest that ghrelin could improve muscle wasting in patients with chronic heart failure and cardiac cachexia, a severe catabolic state characterized by weight loss and muscle wasting, resistant to long-term treatment with nutritional supplements.
PubMedID- 23178647 muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (sica-hf).
PubMedID- 23665153 This article describes the terminology, molecular pathways, prevalence, clinical implications and possible treatment approaches to muscle wasting in patients with heart failure.
PubMedID- 24094897 Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the studies investigating comorbidities aggravating heart failure (sica-hf).
PubMedID- 25634161 Advanced heart failure is frequently associated with severe muscle wasting, termed cardiac cachexia.
PubMedID- 24595460 The agrin breakdown products totalcaf, caf110 and caf22 were evaluated in heart failure patients with muscle wasting compared to heart failure patients without muscle wasting.
PubMedID- 25918517 This could happen because cancer (all sites combined) and senescent phenotypes such as physical frailty, and heart failure due to muscle atrophy, have peak manifestations at different ages: cancer risk reaches its maximum typically before oldest old age (<85), while senescence-related causes become major contributors to mortality risk later (at ages 85+) (ukraintseva and yashin, 2003a,b; ukraintseva et al., 2008; akushevich et al., 2012).
PubMedID- 25888309 Pro-inflammatory il-6 has been reported to be involved in the remodeling of left ventricle after myocardial infarction and induced heart failure leading to skeletal muscle atrophy and heart disorders [25,26].

Page: 1